CT130: A GLP-1 Drug Built to Take Breaks

Researchers led by Wei Ding described a new experimental GLP-1 receptor agonist called CT130 in a paper published online on September 8, 2026, in the journal Diabetes, Obesity and Metabolism^[1]. CT130 is built from semaglutide, the molecule sold as Ozempic, Wegovy and Rybelsus, but instead of once-weekly dosing it is designed to be given every two weeks, with a deliberate drug-free gap built into the schedule. The paper's argument is that giving the GLP-1 receptor, the protein on cells that the drug activates, time off between doses could improve effectiveness, protect the receptor itself, and cut the stomach side effects that make people quit GLP-1 drugs, all at once.

What CT130 actually is

CT130 is not on the market and has not been given to a human volunteer in any published trial. It is a laboratory compound tested so far in cell-binding assays, rats, two strains of obese mice, and a small pilot in non-human primates^[1]. In binding studies the researchers reported an EC50 of 21 picomolar, a measure of how little drug it takes to activate the receptor, where a lower number means a more potent binder. They also reported a half-life, the time it takes for half the drug to clear the body, of 13.9 hours in rats, about 1.4 times longer than semaglutide measured the same way^[1]. A longer half-life is part of why the researchers built the schedule around two-week gaps rather than the once-weekly schedule used for semaglutide.

The mouse numbers so far

The core comparison in the paper pits biweekly CT130 against weekly semaglutide in two obese mouse models: B6/ob mice, which carry a genetic mutation that makes them obese, and diet-induced obese mice, which gain weight from eating more calories than they burn, closer to how most human patients become overweight. Across both models, CT130 outperformed semaglutide on body-weight reduction, glucose tolerance, total cholesterol, LDL cholesterol and body-fat percentage^[1]. The paper also proposes a reason why. Continuous weekly exposure to semaglutide pushed the GLP-1 receptor toward what the authors call progressive internalization, meaning cells pull the receptor inside and it does not fully resurface before the next dose. The drug-free interval in the CT130 schedule instead allowed what the paper calls near-complete receptor recycling, restoring receptor numbers on the cell surface before the following dose arrived^[1].

Two findings stood outside the weight and glucose numbers. CT130 lowered cholesterol partly by suppressing SREBP-2, a protein inside cells that switches on cholesterol production, which the paper describes as a mechanism distinct from how semaglutide works^[1]. And on the gastrointestinal side, CT130-treated animals showed higher fecal water content, which the researchers read as a sign of reduced constipation risk^[1], a direct answer to one of the most common complaints reported by people taking GLP-1 drugs already on the market.

The toxicology and primate numbers

In rodent and primate toxicology testing, the researchers found no adverse findings at doses up to 200 times the human-equivalent semaglutide dose^[1]. The primate work in the paper is a small pilot rather than a dose-ranging programme: two biweekly doses of CT130 produced more than 10% weight loss in the animals tested, with what the paper describes as a good safety profile^[1]. That is one early readout in a handful of animals, not a controlled trial, and it says nothing yet about how CT130 would perform, or how safe it would be, in people.

What this is not

CT130 has no marketing authorization anywhere. Semaglutide, by contrast, has been a prescription-only medicine in the European Union since the European Commission authorised Ozempic in February 2018^[3], and the STEP-1 trial reported a mean body-weight reduction of 14.9% at 68 weeks on semaglutide 2.4 mg weekly, against 2.4% on placebo, in adults with overweight or obesity^[2]. That same trial recorded the practical cost of the gastrointestinal side effects CT130 is designed around: 4.5% of participants on semaglutide stopped treatment because of gastrointestinal adverse events, mostly nausea and diarrhea, against 0.8% on placebo^[2]. CT130's animal results describe a much earlier stage of development. The amounts given to rats, mice and primates in the paper are research doses chosen for those experiments, not a human dosing recommendation, and nothing here should be read as one.

Why this matters

Gastrointestinal side effects are the main reason patients stop taking GLP-1 drugs already on the market, whether that is semaglutide or the dual GIP and GLP-1 agonist tirzepatide, sold as Mounjaro and Zepbound. Drug developers are approaching that problem from different directions. Tirzepatide and newer candidates change which receptors the molecule hits. CT130 instead changes the dosing rhythm, spacing doses further apart so the receptor gets a break. What the CT130 paper adds is a specific, testable idea rather than a proven one: that letting the GLP-1 receptor recover between doses might improve effectiveness and tolerability together, instead of trading one for the other. Whether that idea holds up in humans is the open question, and the paper gives no timeline for when, or whether, CT130 moves into a human trial.

This article is for educational and journalistic purposes only and does not constitute medical advice. CT130 is an unapproved research compound with no marketing authorisation anywhere and no published human trial data. Peptides discussed here, including semaglutide and tirzepatide, may be classified as prescription medicines depending on your jurisdiction. Always consult a qualified healthcare professional before making any decision about a GLP-1 medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.